Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation

Author(s): Marija M. Polovina, Tatjana S. Potpara

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 8 , Issue 2 , 2013


Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia in clinical practice associated with significant morbidity and mortality. With the growing number of the affected individuals, the development of safe and effective treatment options for AF has become a worldwide priority. Currently available antiarrhythmic medications for the restoration and maintenance of sinus rhythm have limitations due to the modest efficacy and a potential for adverseeffects. Although substantial progress has been made in AF-ablation techniques, broad application of these nonpharmacological treatment modalities is limited and antiarrhythmic drug treatment is still the cornerstone and the first-line therapy for the majority of AF patients. Improvements in the understanding of the principal pathophysiological mechanisms of AF obtained in the last several years have provided promising treatment opportunities. New therapeutic options are based on the more selective targeting of ion channels and intercellular connection proteins predominantly expressed in the atria, the restoration of intracellular Ca2+ homeostasis and the prevention of AF-associated electrical and structural remodeling. In this review, we provide a highlight of the most important pathophysiological mechanisms in AF with a relation to the potential therapeutic interventions, and discuss novel findings regarding the current and future pharmacological AF management and recent patents.

Keywords: Arrhythmia, antiarrhythmic drugs, atrial fibrillation, ion channels.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 31 July, 2013
Page: [112 - 126]
Pages: 15
DOI: 10.2174/15748901113089990016
Price: $65

Article Metrics

PDF: 29